Log in to see the prices.
The price above is a net price.
The TBEV (qPCR) product is used to detect sequences specific to tick-borne encephalitis virus (TBEV) in RNA preparations obtained from ticks and cerebrospinal fluid.
Kit size: 100 reactions
Reaction: duplex (FAM: TBEV, HEX: internal control)
Internal control: exogenous/endogenous
Determination: qualitative/quantitative
Kit components:
Tick-borne encephalitis virus (Tick-borne encephalitis virus, TBEV) belongs to the genus Flavivirus in the family Flaviviridae. It is a causative agent of acute central nervous system (CNS) diseases in humans and animals. TBEV is transmitted in nature by Ixodes tick species and rodents, and humans are generally infected through the bite of an infected tick.
The virus is widespread across a large area of Europe and Asia, and is divided geographically and genetically into three subtypes: Far Eastern (FE), Siberian (Sib), and European (Eu). The vector for the FE and Sib subtypes is Ixodes persulcatus, and for the Eu subtype — Ixodes ricinus. It has been suggested that the FE subtype causes a more severe course of the disease than other subtypes, although the incidence rate of the disease varies across Europe and Russia. This may be at least partly due to the selective recording of mainly severe cases in these areas.
TBEV infections in humans have a characteristic biphasic course involving acute febrile illness and a period of apparent convalescence, followed by neurological syndrome. Neurological symptoms include headache, meningitis, meningoencephalitis, and encephalitis, with the latter observed in the most severe cases. Death usually occurs within 5 to 7 days of the onset of neurological symptoms.
Over the past 20 years, a significant increase (over 400%) in tick-borne encephalitis cases has been observed. New outbreaks of the virus appear every year in virtually all European countries, except for the Mediterranean. In recent years, approximately 200,000 clinical cases of TBE have been recorded in Europe and Asia. However, these figures are highly estimated and may represent only 30% of all TBEV infections, as they only concern registered, i.e., hospitalized, cases of TBE. To date, there is no drug on the market that has demonstrated efficacy against TBE.
